Retained Earnings (Accumulated Deficit) of VERTEX PHARMACEUTICALS INC / MA from 31 Mar 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
VERTEX PHARMACEUTICALS INC / MA quarterly Retained Earnings (Accumulated Deficit) in USD history and change rate from 31 Mar 2010 to 31 Dec 2025.
  • VERTEX PHARMACEUTICALS INC / MA Retained Earnings (Accumulated Deficit) for the quarter ending 31 Dec 2025 was $13,560,000,000, a 41% increase year-over-year.
Source SEC data
View on sec.gov
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Change (%)

VERTEX PHARMACEUTICALS INC / MA Quarterly Retained Earnings (Accumulated Deficit) (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $13,560,000,000 +$3,953,200,000 +41% 31 Dec 2025 10-K 13 Feb 2026 2025 FY
Q3 2025 $12,368,900,000 +$3,675,100,000 +42% 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $11,286,000,000 +$3,637,600,000 +48% 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $10,253,100,000 -$988,900,000 -8.8% 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $9,606,800,000 -$535,600,000 -5.3% 31 Dec 2024 10-K 13 Feb 2026 2025 FY
Q3 2024 $8,693,800,000 -$479,800,000 -5.2% 30 Sep 2024 10-Q 05 Nov 2024 2024 Q3
Q2 2024 $7,648,400,000 -$489,900,000 -6% 30 Jun 2024 10-Q 02 Aug 2024 2024 Q2
Q1 2024 $11,242,000,000 +$4,019,400,000 +56% 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 $10,142,400,000 +$3,619,600,000 +55% 31 Dec 2023 10-K 13 Feb 2025 2024 FY
Q3 2023 $9,173,600,000 +$3,469,700,000 +61% 30 Sep 2023 10-Q 07 Nov 2023 2023 Q3
Q2 2023 $8,138,300,000 +$3,364,900,000 +70% 30 Jun 2023 10-Q 02 Aug 2023 2023 Q2
Q1 2023 $7,222,600,000 +$3,259,700,000 +82% 31 Mar 2023 10-Q 02 May 2023 2023 Q1
Q4 2022 $6,522,800,000 +$3,322,000,000 +104% 31 Dec 2022 10-K 15 Feb 2024 2023 FY
Q3 2022 $5,703,900,000 +$3,273,241,000 +135% 30 Sep 2022 10-Q 28 Oct 2022 2022 Q3
Q2 2022 $4,773,400,000 +$3,194,669,000 +202% 30 Jun 2022 10-Q 05 Aug 2022 2022 Q2
Q1 2022 $3,962,900,000 +$2,451,093,000 +162% 31 Mar 2022 10-Q 06 May 2022 2022 Q1
Q4 2021 $3,200,800,000 +$2,342,100,000 +273% 31 Dec 2021 10-K 10 Feb 2023 2022 FY
Q3 2021 $2,430,659,000 +$2,176,180,000 +855% 30 Sep 2021 10-Q 03 Nov 2021 2021 Q3
Q2 2021 $1,578,731,000 +$1,991,686,000 30 Jun 2021 10-Q 30 Jul 2021 2021 Q2
Q1 2021 $1,511,807,000 +$2,762,032,000 31 Mar 2021 10-Q 30 Apr 2021 2021 Q1
Q4 2020 $858,700,000 +$2,711,678,000 31 Dec 2020 10-K 09 Feb 2022 2021 FY
Q3 2020 $254,479,000 +$2,690,691,000 30 Sep 2020 10-Q 30 Oct 2020 2020 Q3
Q2 2020 $412,955,000 +$2,080,775,000 +83% 30 Jun 2020 10-Q 31 Jul 2020 2020 Q2
Q1 2020 $1,250,225,000 +$1,510,932,000 +55% 31 Mar 2020 10-Q 01 May 2020 2020 Q1
Q4 2019 $1,852,978,000 +$1,136,500,000 +38% 31 Dec 2019 10-K 11 Feb 2021 2020 FY
Q3 2019 $2,436,212,000 +$2,103,793,000 +46% 30 Sep 2019 10-Q 31 Oct 2019 2019 Q3
Q2 2019 $2,493,730,000 +$2,175,021,000 +47% 30 Jun 2019 10-Q 01 Aug 2019 2019 Q2
Q1 2019 $2,761,157,000 +$2,114,954,000 +43% 31 Mar 2019 10-Q 01 May 2019 2019 Q1
Q4 2018 $2,989,478,000 +$2,130,245,000 +42% 31 Dec 2018 10-K 13 Feb 2020 2019 FY
Q3 2018 $4,540,005,000 +$680,402,000 +13% 30 Sep 2018 10-Q 25 Oct 2018 2018 Q3
Q2 2018 $4,668,751,000 +$448,704,000 +8.8% 30 Jun 2018 10-Q 26 Jul 2018 2018 Q2
Q1 2018 $4,876,111,000 +$259,340,000 +5% 31 Mar 2018 10-Q 27 Apr 2018 2018 Q1
Q4 2017 $5,119,723,000 +$254,113,000 +4.7% 31 Dec 2017 10-K 13 Feb 2019 2018 FY
Q3 2017 $5,220,407,000 +$186,374,000 +3.4% 30 Sep 2017 10-Q 30 Oct 2017 2017 Q3
Q2 2017 $5,117,455,000 +$250,485,000 +4.7% 30 Jun 2017 10-Q 28 Jul 2017 2017 Q2
Q1 2017 $5,135,451,000 +$167,964,000 +3.2% 31 Mar 2017 10-Q 28 Apr 2017 2017 Q1
Q4 2016 $5,373,836,000 -$112,052,000 -2.1% 31 Dec 2016 10-K 15 Feb 2018 2017 FY
Q3 2016 $5,406,781,000 -$218,728,000 -4.2% 30 Sep 2016 10-Q 31 Oct 2016 2016 Q3
Q2 2016 $5,367,940,000 -$275,036,000 -5.4% 30 Jun 2016 10-Q 01 Aug 2016 2016 Q2
Q1 2016 $5,303,415,000 -$399,359,000 -8.1% 31 Mar 2016 10-Q 03 May 2016 2016 Q1
Q4 2015 $5,261,784,000 -$556,334,000 -12% 31 Dec 2015 10-K 23 Feb 2017 2016 FY
Q3 2015 $5,188,053,000 -$659,259,000 -15% 30 Sep 2015 10-Q 30 Oct 2015 2015 Q3
Q2 2015 $5,092,904,000 -$734,170,000 -17% 30 Jun 2015 10-Q 04 Aug 2015 2015 Q2
Q1 2015 $4,904,056,000 -$704,704,000 -17% 31 Mar 2015 10-Q 04 May 2015 2015 Q1
Q4 2014 $4,705,450,000 -$738,555,000 -19% 31 Dec 2014 10-K 16 Feb 2016 2015 FY
Q3 2014 $4,528,794,000 -$517,614,000 -13% 30 Sep 2014 10-Q 06 Nov 2014 2014 Q3
Q2 2014 $4,358,734,000 -$471,686,000 -12% 30 Jun 2014 10-Q 31 Jul 2014 2014 Q2
Q1 2014 $4,199,352,000 -$369,469,000 -9.6% 31 Mar 2014 10-Q 05 May 2014 2014 Q1
Q4 2013 $3,966,895,000 -$445,028,000 -13% 31 Dec 2013 10-K 13 Feb 2015 2014 FY
Q3 2013 $4,011,180,000 -$565,461,000 -16% 30 Sep 2013 10-Q 07 Nov 2013 2013 Q3
Q2 2013 $3,887,048,000 -$498,872,000 -15% 30 Jun 2013 10-Q 02 Aug 2013 2013 Q2
Q1 2013 $3,829,883,000 -$506,638,000 -15% 31 Mar 2013 10-Q 08 May 2013 2013 Q1
Q4 2012 $3,521,867,000 -$107,032,000 -3.1% 31 Dec 2012 10-K 11 Feb 2014 2013 FY
Q3 2012 $3,445,719,000 +$127,745,000 +3.6% 30 Sep 2012 10-Q 06 Nov 2012 2012 Q3
Q2 2012 $3,388,176,000 +$406,398,000 +11% 30 Jun 2012 10-Q 08 Aug 2012 2012 Q2
Q1 2012 $3,323,245,000 +$297,260,000 +8.2% 31 Mar 2012 10-Q 10 May 2012 2012 Q1
Q4 2011 $3,414,835,000 +$29,574,000 +0.86% 31 Dec 2011 10-K 01 Mar 2013 2012 FY
Q3 2011 $3,573,464,000 -$309,447,000 -9.5% 30 Sep 2011 10-Q 03 Nov 2011 2011 Q3
Q2 2011 $3,794,574,000 -$739,514,000 -24% 30 Jun 2011 10-Q 09 Aug 2011 2011 Q2
Q1 2011 $3,620,505,000 -$765,451,000 -27% 31 Mar 2011 10-Q 06 May 2011 2011 Q1
Q4 2010 $3,444,409,000 31 Dec 2010 10-K 22 Feb 2012 2011 FY
Q3 2010 $3,264,017,000 30 Sep 2010 10-Q 28 Oct 2010 2010 Q3
Q2 2010 $3,055,060,000 30 Jun 2010 10-Q 03 Aug 2010 2010 Q2
Q1 2010 $2,855,054,000 31 Mar 2010 10-Q 03 May 2010 2010 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.